Bristol Myers Squibb's Krazati, in combination with cetuximab, failed to significantly improve survival rates in metastatic colorectal cancer patients compared to chemotherapy. Meanwhile, the European Medicines Agency has initiated a rolling review of Revolution Medicines' experimental treatment for pancreatic cancer. Additionally, HitGen announced that its partner BioAge Labs has commenced a Phase 2 clinical trial for BGE-102, an oral inhibitor targeting cardiovascular risk.
Alexandria Real Estate reached 95.4% occupancy at its San Diego megacampus following the completion of a major R&D facility for Bristol Myers Squibb.
Read the full storyHitGen announced that partner BioAge Labs has started Phase 2 clinical trials for BGE-102, an oral inhibitor targeting cardiovascular risks.
The EMA has initiated a rolling review for an experimental metastatic pancreatic cancer treatment, potentially accelerating the regulatory approval timeline.
Krazati failed to meet primary survival endpoints in a Phase 3 study, threatening its regulatory status for KRAS G12C-mutated colorectal cancer.